Improving Therapeutic Adherence in Cardiovascular Secondary Prevention.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-31

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this open label randomized controlled trial is to evaluate the efficacy of an intervention through health education based on the Chronic Care Model's implementation to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The main questions it aims to answer are:

* Null hypothesis (H0): In patients in cardiovascular secondary prevention, an intervention based on the application of the Chronic Care Model does not improve therapeutic adherence to the 3 preventive drugs: Angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers, acetylsalicylic acid, and statins.
* Alternative hypothesis (H1): In patients in cardiovascular secondary prevention, an intervention based on the application of the Chronic Care Model improves therapeutic adherence to the 3 preventive drugs: Angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers, acetylsalicylic acid, and statins.

Researchers will compare intervention group (health education, use of mobile phones, personalized dosage system) to the control group (routine follow-up).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Improving Cardiac Secondary Prevention

NCT03269708

Myocardial Infarction Secondary Prevention

ACTIVE_NOT_RECRUITING NA

Improvement of Physical and Physiological Parameters Through the Use of a Mobile App

NCT05093803

Hypertension Diet, Healthy Body Weight +3 more

COMPLETED NA

Adapting and Testing a Novel Digital Health Tool (PREVENT) to Improve Health Behavior Counseling and Cardiovascular Health in Rural Primary Care Clinics

NCT06063564

Obesity Cardiovascular Diseases

RECRUITING NA

Effectiveness New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based

NCT01826929

Ischemic Heart Disease

UNKNOWN NA

Effects of Primary Prevention in Elderly People-The Healthy Aging Initiative

NCT03312439

Cardiovascular Diseases Non-communicable Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cardiovascular diseases are the worldwide's leading cause of mortality. Within the spectrum of these diseases, cerebrovascular disease, coronary heart disease, and peripheral vascular disease are included. Secondary prevention is an effective strategy in patients with previous events, being the most used drugs antihypertensives, statins and salicylic acetyl acid.

Therapeutic adherence in these patients is crucial, as the lack of it, results in increased morbidity and mortality, as well as decreased quality of life and raised healthcare costs. However, less than half of the patients take all three medications during the first year. In addition, the lack of therapeutic adherence is easier to measure in the primary care setting.

Objective: To evaluate the efficacy of an intervention through health education based on the Chronic Care Model's implementation to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease.

Methods: Open label randomized controlled trial, selecting patients presenting the inclusion criteria through consecutive probability sampling. Random assignment will be carried out using a random number table.

Intervention on patients in the experimental group will be conducted through health education following the recommendations of the Chronic Care Model (CCM). The aim is to empower patients to manage their disease through therapeutic education measures and shared decision-making with the patient.

Two individual sessions (one in the first month and another in the fourth month) and four group sessions (one per quarter with 5 to 10 patients) will be conducted. The individual sessions will last 30 minutes, and the group sessions will last 1 hour.

In the first quarter, an individual session will be held in the first month, followed by a group session in the second month. In the second quarter, another individual session will be held in the fourth month, and a group session in the sixth month. Subsequently, group sessions will continue with one scheduled in the ninth month and another in the twelfth month.

Considering a therapeutic adherence of 50% in the control group and an expected therapeutic adherence of 80% in the intervention group, with a type II error of 20% (80% power), a type I error of 5% (95% confidence interval), and a 15% loss rate, a sample size of 45 patients in each group is estimated.

The follow-up period will be conducted for one year. After data collection, a descriptive univariate analysis of the variables and a bivariate analysis will be performed. Finally, a multivariate analysis will be conducted to isolate potential confounding factors and to analyze the impact of the intervention on therapeutic adherence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases Chronic Disease Secondary Prevention Coronary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Intervention group: health education, use of mobile phones, personalized dosage system.

Group Type EXPERIMENTAL

(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease

Intervention Type BEHAVIORAL

The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:

Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.

Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.

Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.

Personalized Dosing Systems (PDS): Helping manage medication intake.

Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet.

Control group

Routine follow-up.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

(Health education program) To increase therapeutic adherence in patients with secondary prevention for cardiovascular disease

The intervention involves a comprehensive health education program based on the Chronic Care Model to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The program includes the following components:

Health Education Sessions: Education on the importance of adherence, understanding the disease, side effects of medications, and their management. It addresses personal beliefs and concerns.

Mobile Phone Reminders: Use of alarms and the ti.care® app to remind patients to take their medications.

Medication Verification: Ensuring that the medications and dosages taken match the prescriptions.

Personalized Dosing Systems (PDS): Helping manage medication intake.

Additional Health Advice: Control of other cardiovascular risk factors and benefits of the Mediterranean diet.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes, aged over 18 years old, who, after reading the patient information sheet, provide written informed consent.
* Patients in secondary prevention receiving daily single-dose angiotensin converting enzyme inhibitors/Angiotensin II receptor blockers, acetylsalicylic acid, and statins for 6 months or more.
* Diagnosis of any of the following cardiovascular diseases: cerebrovascular disease, ischemic heart disease, or peripheral vascular disease.
* Patients under follow-up at our primary care center.
* Patients identified with therapeutic adherence deficiency, defined as Haynes-Sackett test supplemented with Medication Possession Ratio (MPR) \< 80% for any of the 3 drugs in the previous 6 months.

Exclusion Criteria

* Patients who refuse to participate.
* Incomplete completion of informed consent.
* Language barrier.
* Patients diagnosed with psychiatric, psychological, neurological, and/or social problems that hinder intervention or follow-up.
* Life expectancy less than one year.
* Patients whose treatment is managed by a caregiver (professional or family member).
* Patients with Barthel Index \<60.
* Institutionalized patients.
* Patients currently participating in similar research studies.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No